Colesevelam hydrochloride

Colesevelam hydrochloride 是一种具有口服活性的胆汁酸螯合剂、调脂剂和血糖控制剂,可结合胃肠道中的胆汁酸形成不可吸收的复合物,中断肠肝循环并增加粪便胆汁酸的排泄,调控 FXR、TGR5 和 Cyp7a1 的活性,触发 cAMP 信号传导并促进 GLP-1 的释放,同时改变肝脏脂质和葡萄糖代谢,抑制肝糖原分解,降低肝脏甘油三酯和胆固醇水平,并加快 LDL-C 低密度脂蛋白胆固醇的清除,可用于 2 型糖尿病、高胆固醇血症和酒精相关性肝病的研究。
产品编号: MS-T99746 纯度: 95.0% CAS No.: 182815-44-7 分子式: (C3H8NCl)2.(C9H20N2OCl2).(C13H28NCl)7.(C12H28N2Cl2)6 分子量: 3694.64
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价
(0.1 - 0.2mg)
询价
询价

产品描述

Colesevelam hydrochloride 是一种具有口服活性的胆汁酸螯合剂、调脂剂和血糖控制剂,可结合胃肠道中的胆汁酸形成不可吸收的复合物,中断肠肝循环并增加粪便胆汁酸的排泄,调控 FXR、TGR5 和 Cyp7a1 的活性,触发 cAMP 信号传导并促进 GLP-1 的释放,同时改变肝脏脂质和葡萄糖代谢,抑制肝糖原分解,降低肝脏甘油三酯和胆固醇水平,并加快 LDL-C 低密度脂蛋白胆固醇的清除,可用于 2 型糖尿病、高胆固醇血症和酒精相关性肝病的研究。

生物实验数据

生物活性 Colesevelam hydrochloride is an orally active bile acid sequestrant, lipid-lowering agent, and glycemic control agent that binds bile acids in the gastrointestinal tract to form non-absorbable complexes, interrupts the enterohepatic circulation, and increases fecal bile acid excretion; it modulates the activity of FXR, TGR5, and Cyp7a1, triggers cAMP signaling, and promotes GLP-1 release, while altering hepatic lipid and glucose metabolism, inhibiting hepatic glycogenolysis, reducing hepatic triglyceride and cholesterol levels, and accelerating the clearance of LDL-C low-density lipoprotein cholesterol, and it can be used for research on type 2 diabetes, hypercholesterolemia, and alcohol-related liver disease.
IC50 & Target

PKA

 

体外研究
(In Vitro)

Colesevelam hydrochloride (5 mg/mL; 45 min incubation with taurocholic acid and oleic acid, followed by real-time cell treatment) 可与牛磺胆酸形成复合物,该复合物能在 HEK293 TGR5-BRET 细胞中激活人源 TGR5 介导的 cAMP 信号通路,表明结合于 Colesevelam hydrochloride 的胆汁酸仍保留 TGR5 激动剂活性。
Colesevelam hydrochloride (孵育 1 小时) 在常见饮料中混悬后仍保持稳定的胆汁酸结合亲和力与结合能力;在生理条件下,其总胆汁酸结合能力 (包括对 GC 的更高亲和力) 优于传统胆汁酸螯合剂,且效力是这些传统药物的 4 至 6 倍。

体内研究
(In Vivo)

Colesevelam hydrochloride (2%;口服;自由摄取;7 天) 可通过 TGR5/GLP-1 依赖型机制抑制饮食诱导肥胖小鼠的肝糖原分解并降低高血糖,同时通过 FXR 依赖、TGR5/GLP-1 非依赖型机制改善胆固醇代谢。
Colesevelam hydrochloride (直肠给药) 与牛磺胆酸形成的复合物足以在正常小鼠中诱导 GLP-1 的释放。
Colesevelam hydrochloride (2%;口服;每日;自第 6 天起至研究结束) 处理可通过减少肝脏脂质蓄积及相关基因表达,缓解人源化无菌小鼠中乙醇诱导的肝脏脂肪变性,但会显著升高血清肝损伤标志物,且无法改善肠道屏障功能。

Animal Model: C57Bl/6J wild-type (male);
Dosage: 2%
Administration: oral; ad libitum; 7 days
Result: Normalized hepatic cholesterol levels.
Reduced fed plasma glucose concentrations and glucose excursion during glucose tolerance tests.
Alleviated hyperinsulinemia in diet-induced obese mice.
Decreased basal endogenous glucose production by suppressing hepatic glycogenolysis without altering gluconeogenic flux.
Elevated hepatic glycogen content in fed wild-type mice.
Animal Model: TGR5 knockout (male); FXR knockout (male)
Dosage: 2%
Administration: oral; ad libitum; 7 days
Result: Increased portal GLP-1 levels in wild-type lean and obese mice but not in TGR5-knockout mice.
Blocked the suppression of hepatic glycogenolysis and attenuated glucose lowering when coadministered with the GLP-1 receptor antagonist exendin-(9–39).
Retained the ability to reduce hyperinsulinemia despite GLP-1 receptor inhibition.
Reduced hepatic cholesterol levels in both wild-type and TGR5-knockout mice.
Induced hepatic expression of the cholesterol biosynthetic genes Cyp7a1 and Hmgcs.
Increased de novo cholesterol synthesis by sevenfold.Moderately reduced plasma insulin and decreased plasma glucose similarly in FXR-knockout mice.
Animal Model: C57BL/6 (female, 5-6 weeks old, germ-free, colonized with feces from alcoholic hepatitis patients, chronic-binge ethanol feeding model)
Dosage: 2% (by dry powder weight)
Administration: oral; daily; from day 6 until study end
Result: Reduced hepatic triglyceride and cholesterol levels.
Reduced hepatic mRNA expression of lipogenic and cholesterol synthesis genes (Acc1, Fasn, Hmgcr, Srebp1c) and ethanol-metabolizing genes (Adh1, Cyp2e1).
Reduced hepatic Cyp7a1 protein and Cyp27a1 mRNA expression.
Reduced hepatic Mpo (neutrophil marker) mRNA expression.
Significantly increased serum ALT and ALP levels.
Did not reduce serum bile acid levels, nor improve intestinal barrier function (serum LPS levels unchanged).
性状 固体
颜色 White to light yellow

化学信息

分子量 3694.64
分子式 (C3H8NCl)2.(C9H20N2OCl2).(C13H28NCl)7.(C12H28N2Cl2)6
CAS No. 182815-44-7

储存&溶解度

溶解度信息
DMSO: Slightly soluble
储存方式

-20°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础